Clinical Oncology
Volume 21, Issue 8 , Pages 610-616 , October 2009

Effect of the UK Postcode Lottery on Survival of Patients with Metastatic Renal Cancer: an Audit of Outcomes in Patients with Metastatic Renal Cancer Suitable for Treatment with Tyrosine Kinase Inhibitors

  • N. James

      Affiliations

    • Cancer Centre, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham B15 2TH, UK
    • Cancer Research UK Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
    • Cancer Research UK Clinical Trials Unit, Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
    • ,
  • J. Pascoe

      Affiliations

    • Cancer Centre, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham B15 2TH, UK
    • Cancer Research UK Clinical Trials Unit, Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
    • Corresponding Author InformationAuthor for correspondence: N. James, CRUK Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. Tel: +44-121-414-4097.
    • ,
  • A. Zachariah

      Affiliations

    • Cancer Centre, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham B15 2TH, UK
    • ,
  • D. Ray

      Affiliations

    • Quality Outcomes Research Unit, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham B15 2TH, UK
    • ,
  • A. Oldroyd

      Affiliations

    • Cancer Centre, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham B15 2TH, UK
    • ,
  • H. Parry

      Affiliations

    • Cancer Centre, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham B15 2TH, UK
    • ,
  • H. Benghiat

      Affiliations

    • Cancer Centre, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham B15 2TH, UK
    • ,
  • M. Karina

      Affiliations

    • Cancer Centre, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham B15 2TH, UK
    • ,
  • S. Collins

      Affiliations

    • Cancer Research UK Clinical Trials Unit, Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
    • ,
  • E. Porfiri

      Affiliations

    • Cancer Centre, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham B15 2TH, UK
    • Cancer Research UK Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
    • Cancer Research UK Clinical Trials Unit, Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK

Received 19 October 2008 ,Revised 13 May 2009 ,Accepted 23 June 2009.

References 

  1. National Institute for Health and Clinical Excellence (NICE) . Renal cell carcinoma – bevacizumab, sorafenib, sunitinib and temsirolimus: evaluation report. Available from: http://www.nice.org.uk/guidance/index.jsp?action = folder&o = 41474
  2. Clarke R, Waddell T, Gallagh J, et al. A postcode lottery still exists for cancer patients with exceptional circumstances. Clin Oncol (R Coll Radiol). 2008;20(10):771–772
  3. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(1):16–24
  4. Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2005;23(Suppl):abstract LBA4510.
  5. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–134
  6. Bukowski RM, Eisen T, Szczylik C, et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J Clin Oncol. 2007;25:(ASCO Annual Meeting Proceedings Part I):abstract 5023.
  7. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–124
  8. Figlin RA, Hutson TE, Tomczak P, et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2008;26(Suppl):abstract 5024
  9. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530–2540
  10. Appleby J, Devlin N, Parkin D. NICE's cost effectiveness threshold. Br Med J. 2007;335:358–359

PII: S0936-6555(09)00189-7

doi: 10.1016/j.clon.2009.06.007

Clinical Oncology
Volume 21, Issue 8 , Pages 610-616 , October 2009

Article Tools

* Image Usage & Resolution